X4 Pharmaceuticals Inc [NASDAQ: XFOR] jumped around 0.26 points on Wednesday, while shares priced at $0.74 at the close of the session, up 52.59%.
Compared to the average trading volume of 3.84M shares, XFOR reached a trading volume of 36639371 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about X4 Pharmaceuticals Inc [XFOR]?
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for XFOR shares is $2.96 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on XFOR stock is a recommendation set at 1.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
B. Riley Securities have made an estimate for X4 Pharmaceuticals Inc shares, keeping their opinion on the stock as Neutral, with their previous recommendation back on December 12, 2023. While these analysts kept the previous recommendation, B. Riley Securities raised their target price to Buy. The new note on the price target was released on August 30, 2023, representing the official price target for X4 Pharmaceuticals Inc stock. Previously, the target price had yet another raise to $3, while Cantor Fitzgerald analysts kept a Overweight rating on XFOR stock.
The Average True Range (ATR) for X4 Pharmaceuticals Inc is set at 0.10, with the Price to Sales ratio for XFOR stock in the period of the last 12 months amounting to 111.95. The Price to Book ratio for the last quarter was 2.08, with the Price to Cash per share for the same quarter was set at 0.79.
How has XFOR stock performed recently?
X4 Pharmaceuticals Inc [XFOR] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 50.69. With this latest performance, XFOR shares dropped by -8.75% in over the last four-week period, additionally sinking by -15.04% over the last 6 months – not to mention a drop of -5.11% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for XFOR stock in for the last two-week period is set at 62.90, with the RSI for the last a single of trading hit 70.13, and the three-weeks RSI is set at 59.20 for X4 Pharmaceuticals Inc [XFOR]. The present Moving Average for the last 50 days of trading for this stock 0.5408, while it was recorded at 0.5408 for the last single week of trading, and 0.7267 for the last 200 days.
X4 Pharmaceuticals Inc [XFOR]: Deeper insight into the fundamentals
X4 Pharmaceuticals Inc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 4.80 and a Current Ratio set at 4.89.
Earnings analysis for X4 Pharmaceuticals Inc [XFOR]
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for XFOR. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for X4 Pharmaceuticals Inc go to 14.52%.
Insider trade positions for X4 Pharmaceuticals Inc [XFOR]
There are presently around $67.66%, or 68.45%% of XFOR stock, in the hands of institutional investors. The top three institutional holders of XFOR stocks are: BAIN CAPITAL LIFE SCIENCES INVESTORS, LLC with ownership of 16.92 million shares, which is approximately 8.4582%. NEA MANAGEMENT COMPANY, LLC, holding 14.99 million shares of the stock with an approximate value of $$8.69 million in XFOR stocks shares; and NEA MANAGEMENT COMPANY, LLC, currently with $$6.19 million in XFOR stock with ownership which is approximately 5.3382%.
